Pathogenic and protective correlates of T cell proliferation in AIDS

Journal of Clinical Investigation

Volumn 98, Issue 3, 1996, Pages 731-740

  Schrier, Rachel D ^a   Wiley, Clayton A ^b   Spina, Celsa ^a   McCutchan, J Allen ^c   Grant, Igor ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

CD4 T cell proliferation; HIV; human; immune response; T cell activation

Indexed keywords

CD4 ANTIGEN;

AIDS RELATED COMPLEX; ALLELE; ANTIGEN SPECIFICITY; ARTICLE; BRAIN INJURY; COGNITIVE DEFECT; CYTOMEGALOVIRUS; DETERIORATION; FEMALE; HERPES SIMPLEX VIRUS; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0029928323     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118845     Document Type: Article

References (60)

1. Saha, K., and P.K.Y. Wong. 1992. Protective role of cytotoxic lymphocytes against murine leukemia virus-induced neurologic disease and immunodeficiency is enhanced by the presence of helper T cells. Virology. 188:921-925.
2. Horn, R.C., R.W. Finberg, S. Mullaney, and R.M. Ruprecht. 1991. Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T-cells. J. Virol. 65:220-224.
3. Walker, B.D., S. Chakrabarti, B. Moss, T.J. Paradis, T. Flynn, A.G. Durno, R.S. Blumberg, J.C. Kaplan, M.S. Hirsch, and R.T. Schooley. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (Lond.). 328:345-350.
4. Darr, E.S., T. Moudgil, R.D. Meyer, and D.D. Ho. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324:961-964.
5. Mackewicz, C.E., H.W. Ortega, and J.A. Levy. 1991. CD8+ cell anti-HIV activity correlated with the clinical state of the infected individual. J. Clin. Invest. 87:1462-1466.
6. Klatzmann, D., F. Barre-Sinoussi, M.T. Nugeyre, C. Danquet, E. Vilmer, and C. Griscelli. 1984. Selective tropism of lymphadenopathy associated virus for helper-inducer T lymphocytes. Science (Wash. DC). 225:59-63.
7. Schrier, R.D., J.A. McCutchan, J.C. Venable, J.A. Nelson, and C.A. Wiley. 1990. T-cell induced expression of HIV in macrophages. J. Virol. 64: 3280-3288.
8. O'Brien, W.A., K. Grovit-Ferbas, A. Namazi, S. Ovcak-Derzic, H. Wang, J. Park, C. Yeramian, S. Mao, and J.A, Zack. 1995. HIV-1 replication can be increased in peripheral blood of seropositive patients following influenza vaccination. Blood. 86:1082-1089.
9. Staprans, S.I., B.I., Hamilton, S.E. Follansbee, T. Elbeik, P. Barbosa, R.M. Grant, and M.B. Feinberg. 1995. Activation of virus replication after vaccination of HIV-1 infected individuals. J. Exp. Med. 182:1727-1737.
10. Heaton, R.K., I. Grant, N. Butters, D.A. White, D. Kirson, J.H. Atkinson, J.A. McCutchan, M.J. Taylor, M. Kelly, R.J. Ellis, T. Wolfson, R. Velin, T.D. Marcotte, J.R. Hesselink, T.L. Jernigan, J. Chandler, M. Wallace, I. Abramson, and HNRC group. 1995. The HNRC 500. Neuropsychology of HIV infection at different disease stages. J. Int. Neuropsychol. Soc. 1:231-251.
11. Schrier, R.D., J.W. Gnann, Jr., R. Landes, C. Lockshin, D. Richman, A. McCutchan, C. Kennedy, M.B.A. Oldstone, and J.A. Nelson. 1989. T cell recognition of HIV synthetic peptides in a natural infection. J. Immunol. 142:1166-1176.
12. Bastin, J., J. Rothbard, J. Davey, I. Jones, and A. Townsend. 1987. Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 165:1508-1523.
13. Delisi, C., and J.A. Berzofsky. 1985. T-cell antigenic sites tend to be amphipathic structures. Proc. Natl. Acad. Sci. USA. 82:7048-7052.
14. Gnann, J.W., P.L. Schwimmbeck, J.A. Nelson, A.B. Truax, and M.B.A. Oldstone. 1987. Diagnosis of AIDS using a 12 amino acid peptide representing a immunodominant epitope of human immunodeficiency virus. J. Infect. Dis. 156:261-267,
15. Wang, A.M., M.V. Doyle, and D.F. Mark. 1989. Quantitation of mRNA by polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 86:9719-9721.
16. Mehta, P., S.J. Gulevich, L.J. Thal, H. Jin, J.M. Olichney, A.J. McCulchan, R. Heaton, C.A. Hurray, D. Kirson, G. Kaplanski, J. Nelson, J.H. Atkinson, M. Wallace, I. Grant, and HNRC group. 1996. Neurological symptoms, not signs, are common in early HIV infection. J. Neuro-AIDS. 1:67-85.
17. Heaton, R.K., I. Grant, W.Z. Anthony, and R.A.W. Lehman. 1981. A comparison of clinical and automated interpretation of the Halstead-Reitan battery. J. Clin. Neuropsychol. 1:121-141.
18. Heaton, R.K., D. Kirson, R.A. Velin, I. Grant, and HNRC group. 1994. The utility of clinical ratings for detecting cognitive change in HIV infection. In Neuropsychology of HIV Infection. I. Grant and A. Martin, editors. Oxford University Press, New York, 188-206.
19. Grant, I., and R.K. Heaton. 1992. Human immunodeficiency virus-type 1 and the brain. J. Consult. Clin. Psychol. 58:22-30.
20. Jabs, D.A., W.R. Green, R. Fox, B.F. Polk, and J.G. Bartlett. 1989. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology. 96:1092-1099.
21. Blysma, S., C. Achim, C.A. Wiley, and W.R. Freeman. 1995. The predictive value of cytomegalovirus retinitis for encephalitis in AIDS. Ophthalmology. 113:89-95.
22. Schrier, R.D., W.R. Freeman, C.A. Wiley, J.A. McCutchan, and HNRC group. 1995. Immune predispositions for cytomegalovirus retinitis in AIDS. J. Clin. Invest. 95:1741-1746.
23. Sheppard, H.W., M.S. Asher, B. McRae, R.E. Anderson, W. Lang, and J.-P. Allain. 1991. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J. Acquired Immune Defic. Syndr. 4:704-712.
24. Phair, J., L. Jacobson, R. Detels, C.R. Rinaldo, A. Sahh, L. Schrager, and A. Munoz. 1992. Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the multicenter AIDS cohort study. J. Acquired Immune Defic. Syndr. 5:490-496.
25. Converse, P.J., T.E. Fehniger, A. Ehrnst, O. Strannegard, and S. Britton. 1991. Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-,CMV+ individuals. Clin. Exp. Immunol. 82:556-559.
26. Epstein, J.S., W.R. Frederick, A.M. Rook, L. Jackson, J.F. Manishewitz, R.E. Mayner, H. Masur, and J.C. Enterline. 1985. Selective defects in cytomegalovirus- and mitogen-induced lymphocyte proliferation and interferon release in patients with acquired immunodeficiency syndrome. J. Infect. Dis. 152:727-733.
27. Trauger, R.J., W.K. Giermakowska, F. Ferre, P.C. Dully, M.R. Wallace, D.E. Lewis, H.J. Beecham, K.G. Burnett, F.C. Jensen, and D.J. Carlo. 1993. Cell mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden. Immunology. 78:611-615.
28. Wahren, B., L. Morfeldt-Mansson, O. Biberfeld, L. Moburg, A. Sonnerberg, P. Ljungman, A. Werner, R. Kurth, R. Gallo, and D. Bolognesi. 1987. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J. Virol. 61:2017-2023.
29. Bentin, J., C.D. Tsoukas, J.A. McCutchan, S.A. Spector, D.D. Richman, and J.H. Vaughan. 1989. Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus. J. Clin. Immunol. 9:159-167.
30. Blatt, S.P., C.W. Hendrix, C.A. Butzin, T.M. Freeman, W.W. Ward, R.E. Hensley, G.P. Melcher, D.J. Donovan, and R.N. Boswell. 1993. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV infected patients. Ann. Intern. Med. 119:177-184.
31. Lucey, D.R., S.A. McGuire, M. Clerici, K. Hall, J. Benton, G. Shearer, and R.N. Boswell. 1991. Comparison of spinal fluid beta2 microglobulin levels with CD4+ T-cell count, in vitro T-helper cell function, and spinal fluid IgG parameters in 163 neurologically normal adults infected with the human immunodeficiency virus type 1. J. Infect. Dis. 163:971-975.
32. Sheppard, H.W., W. Lang, M.S. Asher, E. Vittinghoff, and W. Winkelstein. 1993. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS (Philadelphia). 7:1159-1166.
33. Webster, A., C.A. Lee, D.G. Cook, J.F., Grundy, V.C. Emery, P.B.A. Kernoff, and P.D. Griffiths. 1989. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet, 8:63-65.
34. Mosca, L.D., D.P. Bednarici, N.K. Raj, C. Rosen, J.G. Sodroski, W.A. Haseltine, and P.M. Pitha. 1987. Herpes simples virus type 1 can reactivate transcription of latent human immunodeficiency virus. Nature (Lond.). 325:67-70.
35. Skolnik, P.R., B.R. Kosloff, and M.S. Hirsch. 1991. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J. Infect. Dis. 157:508-514.
36. Gendelman, H.E., W. Phelps, L. Feigenbaum, J.M. Ostrove, A. Adachi, P.M. Howley, G. Koury, H.S. Ginsbery, and M.A. Martin. 1986. Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc. Natl. Acad. Sci. USA. 83:9759-9763.
37. Mellors, J.W., L.A. Kingsley, C.R. Rinaldo, J.A. Todd, B.S. Hoo, R.K. Kokka, and P. Gupta. 1995. Ouantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573-579.
38. Saskela, K., C. Stevens, P. Rubinstein, and D. Baltimore. 1994. Human immunodeficiency virus type 1 mRNA expression in peripheral blood predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc. Natl. Acad. Sci. USA. 91:1104-1108.
39. Wiley, C.A., and C.L. Achim. 1994. HIV encephalitis is the pathologic correlate of dementia in AIDS. Ann. Neurol. 36:673-676.
40. Ho, D.D., T.R. Rota, R.T. Schooley, J.C. Kaplan, J.D. Allan, J.E. Groopman, L. Resnick, D. Felsenstein, C.A. Andrews, and M.S. Hirsh. 1985. Isolation of HTLV-III from cerebrospinal fluid and neural tissue of patients with neurologic syndromes related to AIDS. N. Engl. J. Med. 313:1493-1497.
41. Goudsmit, J., F. de Wolf, and D.A. Paul. 1986. Expression of human immunodeficiency virus antigen (HIV-Af) in scrum and cerebrospinal fluid during acute and chronic infection. Lancet. 2:177-180.
42. Schrier, R.D., W.R. Freeman, C.A. Wiley, A.J. McCutchan, and the HNRC. 1994. CMV-specific immune responses and HLA phenotypes of AIDS patients who develop CMV retinitis. Advan. Neuroimmunol. 4-3:327-336.
43. Tiwari, J.L., and P.I. Terasaki. 1985. HLA and Disease Associations. Springer-Verlag, New York.
44. Mann, D.L., C. Murray, R. Yarchoan, W.A. Blattner, and J.J. Goedert. 1988. HLA antigen frequencies in HIV-1 seropositive disease-free individuals and patients with AIDS. J. Acquired Immune Defic. Syndr. 1:13-17.
45. Louie, L.G., B. Newman, and M.C. King. 1991. Influence of host genotype on progression to AIDS among HIV-infected men. J. Acquired Immune Defic. Syndr. 4:814-818.
46. Boccellari, A.A., J.W. Dilley, D.B. Chambers, C.D. Yingling, M.A. Tauber, A.R. Moss, and D.H. Osmond. 1993. Immune function and neuropsychological performance in HIV-1 infected homosexual men. J. Acquired Immune Defic. Syndr. 6:592-601.
47. Kaslow, R.A., M. Carrington, R. Apple, L. Park, A. Munoz, A.J. Saah, J.J. Goedert, C. Winkler, S.J. O'Brien, C. Rinaldo, et al. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-411.
48. Levy, R.M., D.E. Bredesen, and M.L. Rosenblum. 1985. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J. Neurosurg. 62:475-495.
49. Hill, A.V.S., J. Elvin, A.C. Willis, M. Aidoo, C.E.M. Allsopp, F.M. Gotch, X.M. Gao, M. Takiguchi, B.M. Greenwood, A.R.M. Townsend, et al. 1992. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature (Lond.). 360:434-439.
50. Biddison, W.E. 1982. The role of the human major histocompatibility complex in cytotoxic T-cell responses to virus-infected cells. J. Clin. Immunol. 2(1):1-9.
51. Fox, B.S., F.R. Carbone, R.N. Germaine, Y. Patterson, and R.H. Schwartz. 1988. Processing of a minimal antigenic peptide alters its interaction with MHC molecules. Nature (Lond.). 331:538-540.
52. Babbitt, B.P., P.M. Allen, G. Matsueda, E. Haber, and E.R. Unanue. 1985. Binding of immunogenetic peptides to Ia histocompatibility molecules. Nature (Lond.). 317:359-361.
53. Hill, A.V.S., C.E.M. Allsopp, D. Kwiatkowski, N.M. Anstey, P. Twumasi, P.A. Rowe, S. Bennett, D. Brewster, A.J. McMichael, and B.M. Greenwood. 1991. Common West African HLA antigens are associated with protection from severe malaria. Nature (Lond.). 352:595-600.
54. Almarri, A., and J.R. Batchelor. 1994. HLA and hepatitis B infection. Lancet. 344:1194-1195.
55. Ahmed, A.R., H. Strom, S. Bierman, R. Myers-Elliot, J. Tiwari, and P.I. Terasaki. 1982. A study of HLA and DRw antigens in severe recurrent herpes progenitialis (HSV-2) infection. Am. Acad. Dermatol. 6:898-901.
56. Blancho, G., R. Josien, D. Douillard, J.D. Bignon, A. Cesbron, and J.P. Soulillou. 1992. Influence of HLA A-B-DR matching on cytomegalovirus disease after renal transplantation. Evidence that HLA-DR7 matched recipients are more susceptible to cytomegalovirus disease. Transplantation (Baltimore). 54:871-874.
57. Kraat, Y.J., M.H. Christiaans, F.H. Nieman, P.M. van den Berg-Loonen. J.P. van Hoof, and C.A. Bruggman. 1993. Increased frequency of CMV infection in HLA-DR7 matched renal allograft recipients. Lancet. 341:494-495.
58. Jones, E.H., R.J. Biggar, F.K. Nkrumah, and S.D. Lawler. 1980. Study of the HLA system in Burkitt's lymphoma. Hum. Immunol. 3:207-210.
59. Buus, S., A. Sette, S.M. Colon, C. Miles, and H.M. Grey. 1987. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to find immunogenic peptides. Science (Wash. DC). 235:1353.
60. Chicz, R.M., R.G. Urban, J.C. Gorga, D.A.A. Vignali, W.S. Lane, and R.L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27-47.